Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy
Autor: | Kazuyoshi Kitamura, Tatsuya Chiba, Fumihiko Mabuchi, Kiyotaka Ishijima, Shu Omoto, Fumiko Kashiwagi, Takashi Godo, Satoshi Kogure, Teruhiko Goto, Takashi Shibuya, Jhoji Tanabe, Shigeo Tsukahara, Tadaharu Tsuchiya, Toyoaki Tsumura, Takaharu Tokunaga, Osamu Hosaka, Tetsunori Saito, Kenji Kashiwagi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: | |
Zdroj: | Journal of Ophthalmology, Vol 2018 (2018) |
Druh dokumentu: | article |
ISSN: | 2090-004X 2090-0058 |
DOI: | 10.1155/2018/8456764 |
Popis: | Purpose. To assess the efficacy and safety of switching from prostaglandin analog (PGA) monotherapy to tafluprost/timolol fixed-combination (Taf/Tim) therapy. Subjects and Methods. Patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who had received PGA monotherapy for at least 3 months were enrolled. Patients were examined at 1, 2, and 3 months after changing therapies. Subsequently, the patients were returned to PGA monotherapy. The examined parameters included intraocular pressure (IOP) and adverse events. A questionnaire survey was conducted after the switch to Taf/Tim therapy. Results. Forty patients with a mean age of 66.5 ± 10.3 years were enrolled; 39 of these patients completed the study protocol. Switching to Taf/Tim significantly reduced the IOP from 18.2 ± 2.6 mmHg at baseline to 14.8 ± 2.5 mmHg at 1 month, 15.2 ± 2.8 mmHg at 2 months, and 14.9 ± 2.5 mmHg at 3 months (P |
Databáze: | Directory of Open Access Journals |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |